DiaMedica Therapeutics (DiaMedica Therapeutics) Change In Prepaid Assets : $-0.16 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is DiaMedica Therapeutics Change In Prepaid Assets?

DiaMedica Therapeutics's Change In Prepaid Assets for the quarter that ended in Dec. 2023 was $0.70 Mil. It means DiaMedica Therapeutics's Prepaid Assets increased by $0.70 Mil from Sep. 2023 to Dec. 2023 .

DiaMedica Therapeutics's Change In Prepaid Assets for the fiscal year that ended in Dec. 2023 was $-0.16 Mil. It means DiaMedica Therapeutics's Prepaid Assets declined by $0.16 Mil from Dec. 2022 to Dec. 2023 .

DiaMedica Therapeutics Change In Prepaid Assets Historical Data

The historical data trend for DiaMedica Therapeutics's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DiaMedica Therapeutics Change In Prepaid Assets Chart

DiaMedica Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Prepaid Assets

Get a 7-Day Free Trial

0.51

0.06

-0.12

-0.05

-0.16

DiaMedica Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Prepaid Assets	Get a 7-Day Free Trial															0.08	-0.71	0.29	-0.44	0.70

DiaMedica Therapeutics Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.16 Mil.

DiaMedica Therapeutics Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of DiaMedica Therapeutics's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

DiaMedica Therapeutics (DiaMedica Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » Change In Prepaid Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305

Website

https://www.diamedica.com

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

Executives

Jan Stahlberg	10 percent owner	C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57
Scott Kellen	officer: CFO and Secretary	3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Randall Michael Giuffre	director	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Ab Trill	10 percent owner	SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157
Richard D. Pilnik	director	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Dietrich John Pauls	director, officer: President and CEO	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Ii Jacinto	10 percent owner	394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417
David J. Wambeke	officer: Chief Business Officer	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305
Private Ab Tomeqt	10 percent owner	C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435
Koch Thomas Von	10 percent owner	TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47
Ab Tomenterprise	10 percent owner	C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27
Charles Pauling Semba	director	TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Kuntz	director	MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Tanya Lewis	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Julie Vanorsdel Daves	officer: SVP Clinical Development Oper.	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305